CHARLES H. KIRKPATRICK, M.D.; TERRILL K. SMITH
▸Requests for reprints should be addressed to Charles H. Kirkpatrick, M.D., Building 10, Room 11B-13, National Institutes of Health, Bethesda, Maryland 20014.
KIRKPATRICK C., SMITH T.; Chronic Mucocutaneous Candidiasis: Immunologic and Antibiotic Therapy. Ann Intern Med. 1974;80:310-320. doi: 10.7326/0003-4819-80-3-310
Download citation file:
Published: Ann Intern Med. 1974;80(3):310-320.
Ten patients with chronic mucocutaneous candidiasis were studied immunologically and treated with either intravenous amphotericin B, transfer factor, or both of the agents. Five patients (late-onset cases) developed candidiasis after they were 5 years old, had less severe immunologic deficits, and responded to treatment with amphotericin B. Four of these patients have had remissions of 12 to 38 months, and in two patients negative, delayed candida skin tests became positive, suggesting recovery of immunologic function. The other five patients (early-onset cases) developed candidiasis during infancy or early childhood and had severe impairments of cellular immunity, often with complete anergy. Transfer factor from donors with positive skin tests caused conversion of delayed responses in these patients but did not produce beneficial or detrimental clinical effects. Two early-onset, anergic patients then received amphotericin and chronic transfer factor therapy; both have been free of cutaneous candidiasis for more than 2 years.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only